Kailera Therapeutics Prices Initial Public Offering at $16 per Share
Kailera Therapeutics Announces Pricing of Initial Public Offering
Benzinga
Image: Benzinga
Kailera Therapeutics, an advanced biotechnology company focused on obesity care, has priced its initial public offering at $16 per share, aiming to raise approximately $625 million. The shares will begin trading on the Nasdaq Global Select Market under the ticker symbol 'KLRA' on April 17, 2026.
- 01Kailera Therapeutics is offering 39,062,500 shares at $16 each.
- 02The total gross proceeds are expected to be $625 million.
- 03Trading on Nasdaq is set to begin on April 17, 2026.
- 04Underwriters have a 30-day option to purchase an additional 5,859,375 shares.
- 05The offering is managed by J.P. Morgan, Jefferies, and others.
Advertisement
In-Article Ad
Kailera Therapeutics, Inc. (NASDAQ:KLRA), a biotechnology firm specializing in obesity care, has announced the pricing of its initial public offering (IPO) at $16.00 per share, targeting to raise about $625 million. The IPO will consist of 39,062,500 shares, all offered by the company itself. Kailera's stock is expected to start trading on the Nasdaq Global Select Market on April 17, 2026, with the offering anticipated to close on April 20, 2026, pending customary closing conditions. Additionally, the underwriters have been granted a 30-day option to purchase up to 5,859,375 additional shares at the IPO price. The offering is being managed by a consortium of financial institutions including J.P. Morgan and Jefferies. A registration statement has been filed with the Securities and Exchange Commission and became effective on April 16, 2026.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think investing in biotechnology companies is a good strategy?
Connecting to poll...
Read the original article
Visit the source for the complete story.